標 志 性 成 果 |
楊利軍，教授，博士生導師，博士后指導教師，山西省學術技術帶頭人，山西省中青年拔尖創新人才，山西省高校優秀青年學術帶頭人?，F擔任c7c7.app科學技術部部長、醫學科學院常務副院長，兼任山西省醫學會科研管理分會候任主任委員、中國高等教育學會科技管理研究分會理事、山西省專利保護協會常務理事，山西省藥學會應用藥理學專業委員會副主任委員等職務。主要研究方向是小分子多肽靶向藥物研究和腫瘤免疫分子生物學研究。先后承擔國家十二五重大新藥創制課題、國家自然科學基金等多項國家級科研項目，主持山西省重點研發計劃重點項目等省部級課題10余項，獲省級科技獎勵10余項，發表各類學術論文 60 多篇。 1. Qi Zhao, Xing Lv, Yanqun Dong, Hanyu Hong, Yanbo Zheng, Lijun Yang*, Jianhua Gong*. IMB5036 overcomes resistance to multiple chemotherapeutic drugs in human cancer cells through pyroptosis by targeting the KH-type splicing regulatory protein. Life Sciences, 2023, 328:121941 2. Qi Zhao, Yanbo Zheng, Xing Lv, Jianhua Gong,Liju Yang*.IMB5036 inhibits human pancreati c cancer growth primarily through activating necroptosis, Basic Clin Pharmacol Toxicol, 2021, 130 (3): 375-384 3. Chen Junjun, Dai Jie, Kang Zhiming, Yang Ting, Zhao Qi, Zheng Jinxiu, Zhang Xinxin, Zhang Jisheng, Xu Jun, Sun Gongqin,Yang Lijun*,Yang Tao*. A combinatorial strategy for ov ercoming primary and acquired resistance of MEK inhibition in colorectal cancer, Experimental Cell Research, 2020, 393(1): 1-10 4. Lijun Yang, Yutao Wang, Haifeng Zheng,Dong Zhang, Xiangwei Wu, Gongqin Sun, Tao Yang*. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-de pendent mechanisms, Journal of Chemotherapy, 2017, 29(3): 179-188 5. Lijun Yang, Litao Zhang, Lihong Yan, Haifeng Zheng, Peifen Lu, Junjun Chen, Jie Dai, Haibiao Sun, Yong Xu,Tao Yang*. Stability assessment of a new antithrombotic small peptide, Arg-Gly- Asp-Trp-Arg (RGDWR), and its derivative, Biotechnology Letters, 2017, 39(8): 1183-1190 |
0351-3986058 
@126.com 
山西省晉中市榆次區大學街98號 
Copyright @ 版權所有 c7c7.app 醫學科學院 晉ICP備1****084號-1 